[HTML][HTML] Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
…, F Porrot, N Robillard, J Puech, M Prot, F Gallais… - Nature, 2021 - nature.com
The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India 1 , 2 , 3 , 4 – 5 .
Since then, it has become dominant in some regions of India and in the UK, and has spread to …
Since then, it has become dominant in some regions of India and in the UK, and has spread to …
[HTML][HTML] Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
Background Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting
risk of reinfection and durability of vaccine protection. Methods This is a prospective, …
risk of reinfection and durability of vaccine protection. Methods This is a prospective, …
[HTML][HTML] Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France
F Gallais, A Velay, C Nazon, MJ Wendling… - Emerging infectious …, 2021 - ncbi.nlm.nih.gov
We investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific
antibodies and T-cell responses against SARS-CoV-2 and human coronavirus (HCoV) 229E …
antibodies and T-cell responses against SARS-CoV-2 and human coronavirus (HCoV) 229E …
[HTML][HTML] Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March …
…, L Kassegne, N Lefebvre, F Gallais… - …, 2020 - eurosurveillance.org
Background In March 2020, the COVID-19 outbreak was declared a pandemic by the World
Health Organization. Aim Our objective was to identify risk factors predictive of severe …
Health Organization. Aim Our objective was to identify risk factors predictive of severe …
Reduced sensitivity of infectious SARS-CoV-2 variant B. 1.617. 2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
…, F Porrot, N Robillard, J Puech, M Prot, F Gallais… - Biorxiv, 2021 - biorxiv.org
The SARS-CoV-2 B.1.617 lineage emerged in October 2020 in India 1 – 6 . It has since then
become dominant in some indian regions and further spread to many countries. The …
become dominant in some indian regions and further spread to many countries. The …
Sex differences in the evolution of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2
L Grzelak, A Velay, Y Madec, F Gallais… - The Journal of …, 2021 - academic.oup.com
We measured anti-spike (S), nucleoprotein (N), and neutralizing antibodies in sera from 308
healthcare workers with a positive reverse-transcription quantitative polymerase chain …
healthcare workers with a positive reverse-transcription quantitative polymerase chain …
In‐depth virological assessment of kidney transplant recipients with COVID‐19
…, M Della‐Chiesa, M Solis, F Gallais… - American Journal of …, 2020 - Wiley Online Library
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread widely, causing
coronavirus disease 2019 (COVID‐19) and significant mortality. However, data on viral …
coronavirus disease 2019 (COVID‐19) and significant mortality. However, data on viral …
[HTML][HTML] Refining “Long-COVID” by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection
M Scherlinger, R Felten, F Gallais, C Nazon… - Infectious diseases and …, 2021 - Springer
… Marc Scherlinger, Renaud Felten, Floriane Gallais, Samira Fafi-Kramer and Jean Sibilia
wrote the manuscript. Marc Scherlinger, Renaud Felten and Floriane Gallais are co-first authors. …
wrote the manuscript. Marc Scherlinger, Renaud Felten and Floriane Gallais are co-first authors. …
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
R Felten, F Gallais, C Schleiss, E Chatelus… - The Lancet …, 2022 - thelancet.com
Humoral and cell-mediated immune responses are blunted after SARS-CoV-2 vaccination in
patients with a history of CD20 B-cell-depleting treatment. 1 However, vaccination induces …
patients with a history of CD20 B-cell-depleting treatment. 1 However, vaccination induces …
Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
…, A Koenig, N Cognard, C Levi, F Gallais… - Science Translational …, 2022 - science.org
Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection,
are characterized by high coronavirus disease 2019 (COVID-19)–related mortality and …
are characterized by high coronavirus disease 2019 (COVID-19)–related mortality and …